



**Doncaster Place & Bassetlaw Place Medicines Optimisation
Committee (PMOC)
Sections 1&2 (Area Prescribing and Formulary)
Thursday 18th December 2025 12:00 noon
Via MS Teams
Minutes**

Committee Members:	✓ x	Area Prescribing	Formulary
Rao Kolusu (Chair) Doncaster Place	RK	✓	✓
Ewa Gabzdyl (Deputy Chair)(1 rep from Doncaster Place)	EG	x	x
Erica Carmody (only when EG cannot attend)	EC	✓	✓
Rob Wise Bassetlaw Place	RW	x	x
Lee Wilson DBTHFT (1 rep from DBTHFT)	LW	✓	✓
Rachel Wilson DBTHFT (when LW cannot attend)	RaW	x	x
Steve Davies RDaSH FT (1 rep from RDaSH FT)	SD	x	x
Andrew Houston RDaSH FT	AHo	x	x
Rachel Hubbard Doncaster Place	RH	✓	✓
Mallicka Chakrabarty Bassetlaw (Area Prescribing only)	MC	✓	✓
Dean Eggitt LMC	DE	x	x
Rumit Shah LMC (when DE cannot attend)	RS	x	x
Sonia Griffiths (PCD Doncaster 4D)	SG	✓	✓
Pankaj Chatuvedi DBTHFT (Formulary only)	PC	x	x
Charlotte McMurray (SY ICB MO Team) (Only when needed)	CMcM	x	x
Ashley Hill Doncaster MOT (only when needed)	AH	x	x
Karen Jennison Doncaster MOT	KJ	✓	✓
In attendance:			

✓ x – Indication of attendance to each section of the meeting (where required to attend)

SY ICB – South Yorkshire Integrated Care Board

SY – South Yorkshire

IMOC – Integrated Medicines Optimisation Committee

PMOC – Place Medicines Optimisation Committee

MOT – Medicines Optimisation Team

MO – Medicines Optimisation

TLS – Traffic Light System

MPD- Medicines and Product Directory

SCP – Shared Care Protocol

GP- General Practitioner



Agenda Ref	Subject / Action Required	Action Required By
	Welcome, Introductions and Housekeeping: - Fire Alarm Procedure: N/A	
	Apologies for Absence: Apologies were received from Dean Eggitt, Ewa Gabzdyl, Rob Wise In attendance: Erica Carmody in place of Ewa Gabzdyl The meeting was noted at Quorate.	
	Declarations of Interest ICB Register of Interests Rao Kolusu informed the group that he had attended an event in London which was sponsored by Astra Zeneca. The event was focused on asthma and treatment.	
	Notification of Any Other Business <ul style="list-style-type: none"> • Rao Kolusu - GF product consultation decision by SY ICB • Sonia Griffiths – PCN representation changes • Sonia Griffiths – Mounjaro prescribing query 	
12/25/1	Minutes and actions of the last Meeting The minutes of the meeting held in November 2025 were approved as a true record. Action: <ul style="list-style-type: none"> • Karen Jennison will distribute the ratified minutes to the appropriate distribution list. Action log The action log was discussed and updated accordingly. MO Bulletin The November 2025 MO Bulletin was noted.	KJ
12/25/2	Matters arising not on the agenda	
12/25/2.1	Testosterone SCP and proforma Final version The final document was presented for information as was approved at the last meeting. This is now on the website and MPD and will be included in the January MO bulletin for information. It was noted that there is a halt on the electronic proforma project so the proforma should be used as previously via email. Action <ul style="list-style-type: none"> • Karen Jennison to include in the January MO bulletin, highlighting the changes to the SCP 	KJ
11/25/1.4.1	Milk prescribing in Doncaster and Bassetlaw Final version	



	<p>The final version of the Baby Milk prescribing document was presented to the group, with the amendments requested at the last PMOC 1&2 meeting. The document was approved, and the products will be included on the MPD.</p> <p>Action</p> <ul style="list-style-type: none"> Karen Jennison to add the products on to the MPD and the final document to be added to the website / MPD and included in the next MO bulletin. 	KJ								
12/25/3	Matters Arising									
09/25/1.4.3	Hydroxychloroquine retinal screening update was deferred to January 2026									
11/25/1.4.2	Shared Care process (Lithium) – requests from Primary care to secondary care where there is no shared care agreement in place. E.g. new patients who are already on an Amber drug was deferred to January 2026 meeting									
12/25/4	New Business									
12/25/4.1	<p>Rheumatology SCP</p> <p>This document will be amended to include methotrexate sub-cutaneous injections for Doncaster patients but NOT Bassetlaw patients. The amended document will replace the current document on the website/ MPD, once the final amendments have been approved.</p> <p>Action:</p> <ul style="list-style-type: none"> Lee Wilson and Karen Jennison to liaise with rheumatology department at DBTHFT to amend the document. 	LW/KJ								
12/25/5	<p>Formulary and MPD (Medicines and Products Directory) review December 2025. The formulary products were agreed as below:</p> <table border="1"> <thead> <tr> <th>Formulary Section</th> <th>Item</th> <th>Indication</th> <th>PMOC Action</th> </tr> </thead> <tbody> <tr> <td>6.4.1.1</td> <td>Tibolone</td> <td>Menopause symptoms</td> <td>Green with information for off-label use</td> </tr> </tbody> </table> <p>Action:</p> <ul style="list-style-type: none"> Karen Jennison will make the agreed amendments to the MPD. 	Formulary Section	Item	Indication	PMOC Action	6.4.1.1	Tibolone	Menopause symptoms	Green with information for off-label use	KJ
Formulary Section	Item	Indication	PMOC Action							
6.4.1.1	Tibolone	Menopause symptoms	Green with information for off-label use							
12/25/6	Any Other Business									
12/25/6.1	<p>GF product consultation decision by SY ICB Gluten free products are not to be prescribed on FP10 for patients except a small number in exceptional circumstances. Primary care prescribers are advised not to prescribe any new gluten free products. The next phase will be removing current patients prescribed GF products, but this will be done across South Yorkshire in the coming months. No action for PMOC at this point.</p>									
12/25/6.2	<p>PCN representation changes Sonia Griffiths informed the group that her role will soon be changing, and she will be directly employed by a GP practice and will no longer be employed by</p>									



	<p>the PCN. Sonia informed the group that her employers are happy for her to still attend and asked the group if there was any reason why she could not continue to attend the PMOC section 1&2. Rao Kolusu commented that as the chair he felt that there were no potential conflicts and confirmed that Sonia would still be representing primary care pharmacy workforce which is what she has previously done.</p> <p>The group agreed that Sonia Griffiths would remain a valuable contributor to the PMOC 1&2 meetings.</p>																																							
12/25/6.3	<p>Mounjaro prescribing query</p> <p>Sonia Griffiths informed the group that across her PCN there have been several occurrences where endocrinology specialists from DRI have either advised or started Mounjaro for type one diabetic patients and asked GP practices to continue prescribing. The issue being that type 1 patients on insulin require adjustment to doses of insulin when prescribed Mounjaro. The group agreed to contact the DRI endocrinology specialists to Inform them that this has been brought to attention from a medicines management perspective and request some more information and clarity if they are using it regularly in type one diabetics, and if they could provide some advice that we can share with our primary care prescribers how it can be safely done.</p> <p>Action</p> <ul style="list-style-type: none"> • Rachel Hubbard to draft an email to DRI Endocrinology specialists for further information 	RH																																						
12/25/7	<p>Standing Prescribing functions</p>																																							
12/25/7.1	<p>The committee received the TLS list that was agreed at the December 2025 IMOC meetings.</p> <p>Please Note: TLS status finalised at IMOC all items are classified as non-Formulary unless stated otherwise.</p> <p>The following have been agreed as Grey:</p> <table border="1" data-bbox="288 1384 1182 1827"> <thead> <tr> <th>Drug/Product</th> <th>rationale</th> </tr> </thead> <tbody> <tr><td>Trastuzumab deruxtecan</td><td>6</td></tr> <tr><td>Nintedanib</td><td>6</td></tr> <tr><td>Cemiplimab</td><td>2</td></tr> <tr><td>Cangrelor tetrasodium</td><td>2</td></tr> <tr><td>Iptacopan</td><td>1,6</td></tr> <tr><td>Pitolisant</td><td>2</td></tr> <tr><td>Adrenaline (new nasal spray formulation)</td><td>7</td></tr> <tr><td>Pirtobrutinib (new medicine)</td><td>6</td></tr> <tr><td>Serplulimab (new medicine)</td><td>6</td></tr> <tr><td>Teprotumumab (new medicine)</td><td>6</td></tr> <tr><td>Tofersen (new medicine)</td><td>6</td></tr> <tr><td>Zuranolone (new medicine)</td><td>6</td></tr> <tr><td>Seladelpar (new medicine)</td><td>6</td></tr> <tr><td>Omaveloxolone (new medicine)</td><td>7</td></tr> </tbody> </table> <p>The following have been agreed as Red:</p> <table border="1" data-bbox="288 1899 1182 2033"> <tbody> <tr><td>Garadacimab (new medicine)</td><td>1,6</td></tr> <tr><td>Pitolisant</td><td>1</td></tr> <tr><td>Sevelamer</td><td>1</td></tr> <tr><td>Vincristine</td><td>1</td></tr> </tbody> </table>	Drug/Product	rationale	Trastuzumab deruxtecan	6	Nintedanib	6	Cemiplimab	2	Cangrelor tetrasodium	2	Iptacopan	1,6	Pitolisant	2	Adrenaline (new nasal spray formulation)	7	Pirtobrutinib (new medicine)	6	Serplulimab (new medicine)	6	Teprotumumab (new medicine)	6	Tofersen (new medicine)	6	Zuranolone (new medicine)	6	Seladelpar (new medicine)	6	Omaveloxolone (new medicine)	7	Garadacimab (new medicine)	1,6	Pitolisant	1	Sevelamer	1	Vincristine	1	
Drug/Product	rationale																																							
Trastuzumab deruxtecan	6																																							
Nintedanib	6																																							
Cemiplimab	2																																							
Cangrelor tetrasodium	2																																							
Iptacopan	1,6																																							
Pitolisant	2																																							
Adrenaline (new nasal spray formulation)	7																																							
Pirtobrutinib (new medicine)	6																																							
Serplulimab (new medicine)	6																																							
Teprotumumab (new medicine)	6																																							
Tofersen (new medicine)	6																																							
Zuranolone (new medicine)	6																																							
Seladelpar (new medicine)	6																																							
Omaveloxolone (new medicine)	7																																							
Garadacimab (new medicine)	1,6																																							
Pitolisant	1																																							
Sevelamer	1																																							
Vincristine	1																																							



	<table border="1"> <tr><td>Vindesine</td><td>1</td></tr> <tr><td>Vinorelbine</td><td>1</td></tr> <tr><td>Volanesorsen</td><td>1,6</td></tr> <tr><td>vonhog alfa</td><td></td></tr> <tr><td>Voretigene neparvovec</td><td>1,6</td></tr> <tr><td>Voriconazole</td><td>1,6</td></tr> <tr><td>Zidovudine (in combination with other retroviral drugs)</td><td>1,6</td></tr> <tr><td>Zoledronic acid</td><td>1</td></tr> <tr><td>Clozapine</td><td></td></tr> <tr><td>Delgocitinib</td><td>1,6</td></tr> <tr><td>Cabotegravir (Already traffic lighted Red)</td><td>1,6</td></tr> <tr><td>Cemiplimab</td><td>1,6</td></tr> <tr><td>Darolutamide Already traffic lighted</td><td>1,6</td></tr> <tr><td>Abiraterone (originator and generics)</td><td>1,6</td></tr> <tr><td>Nintedanib</td><td>1,6</td></tr> <tr><td>Vorasidenib (new medicine)</td><td>1,6</td></tr> </table> <p>The following has been agreed as Amber:</p> <table border="1"> <tr> <td>Melatonin - For the treatment of sleep disorders in children and young people up to 18 years (off-label use) Now on SY ICB SCP available on website and MPD</td> </tr> </table> <p>Action:</p> <ul style="list-style-type: none"> • Karen Jennison to update the MPD 	Vindesine	1	Vinorelbine	1	Volanesorsen	1,6	vonhog alfa		Voretigene neparvovec	1,6	Voriconazole	1,6	Zidovudine (in combination with other retroviral drugs)	1,6	Zoledronic acid	1	Clozapine		Delgocitinib	1,6	Cabotegravir (Already traffic lighted Red)	1,6	Cemiplimab	1,6	Darolutamide Already traffic lighted	1,6	Abiraterone (originator and generics)	1,6	Nintedanib	1,6	Vorasidenib (new medicine)	1,6	Melatonin - For the treatment of sleep disorders in children and young people up to 18 years (off-label use) Now on SY ICB SCP available on website and MPD		KJ
Vindesine	1																																			
Vinorelbine	1																																			
Volanesorsen	1,6																																			
vonhog alfa																																				
Voretigene neparvovec	1,6																																			
Voriconazole	1,6																																			
Zidovudine (in combination with other retroviral drugs)	1,6																																			
Zoledronic acid	1																																			
Clozapine																																				
Delgocitinib	1,6																																			
Cabotegravir (Already traffic lighted Red)	1,6																																			
Cemiplimab	1,6																																			
Darolutamide Already traffic lighted	1,6																																			
Abiraterone (originator and generics)	1,6																																			
Nintedanib	1,6																																			
Vorasidenib (new medicine)	1,6																																			
Melatonin - For the treatment of sleep disorders in children and young people up to 18 years (off-label use) Now on SY ICB SCP available on website and MPD																																				
12/25/7.2	<p>NICE Guidance The NICE guidance report was received that was discussed at the December 2025 IMOC meeting.</p> <p>Erica Carmody informed the group of the NICE guidance discussed at the November IMOC</p> <p>There were no actions for this group.</p>																																			
12/25/7.3	<p>MHRA - Drug Safety Update & NHS England Patient Safety alerts The Safety report that was discussed at the December 2025 IMOC meeting was received.</p> <p>Erica Carmody informed the group of the items included in the safety report highlighting a safety alert where penicillin and penicillamine had been mixed up when recording an allergy status resulting in harm to a patient.</p> <p>Action:</p> <ul style="list-style-type: none"> • Karen Jennison and Rachel Hubbard to write an article about drugs with similar names for the next bulletin 		KJ/RH																																	
12/25/7.4	<p>IMOC Update – December 2025 IMOC meeting new documents that have been added to SY MO website/ link to MPD: -</p> <ul style="list-style-type: none"> ➤ SY biosimilar statement ➤ SY Melatonin SCP ➤ South Yorkshire ICB Position Statement on preference of SGLT2 inhibitors <p>Action</p> <ul style="list-style-type: none"> • Karen Jennison to include in the next MO bulletin for information 		KJ																																	
12/25/8	<p>Minutes from other groups</p> <p>SY ICB IMOC</p>																																			



	Minutes from November 2025 were received for information.	
	DBTHFT Drug & Therapeutics Committee (Monthly) No minutes available for this meeting	
	RDASH FT TMOG (Monthly) Minutes from October 2025 were received for information.	
	Barnsley Place APC Minutes from October 2025 were received for information.	
	Rotherham Place MMC Minutes October 2025 were received for information.	
	Sheffield Place APG Minutes from November 2025 were received for information.	
	Nottinghamshire No minutes available for this meeting	
	Date and Time of Next Meeting The next PMOC meeting will be held on Thursday 15th January 2026 at 12:00 Noon Via Teams	

